EUCTR2005-003829-31-DE进行中（未招募）不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.
IBSA Institut Biochimique S.A.0 个研究点目标入组 330 人开始时间: 2005年12月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •outpatients of both gender,
- •aged between 18 and 65 years,
- •of Caucasian race,
- •having a unilateral mild-to-moderate muscle contusion of upper or lower limbs that happened within 72 hours before the study entry,
- •having a superficial haematoma of a maximal size of 10 x 14 cm, localised at the affected site,
- •with pain on standardised movement of at least 50 mm on a 100-mm visual analogue scale (VAS) ,
- •whose injury does not need a orthopaedic or surgical treatment, whose injury does not need physiotherapy other than 3 daily ice applications of not more than 20 minutes duration for the first two days of treatment, if applicable,
- •female subjects of childbearing potential (i.e., not status post hysterectomy or tubal ligation) must be using an appropriate method of contraception according to the definition of Note 3 of ICH M3 Guideline (implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner) and must be willing to continue using it throughout the whole study period,
- •female subjects of childbearing potential must have a negative urine pregnancy test at screening/inclusion visit,
- •subjects must be able to comprehend the full nature and purpose of the study, including possible risks and side effects, to co-operate with the Investigator, to comply with the requirements of the entire study and to return for the required examinations,
- •subjects must sign a written informed consent to the participation prior to inclusion in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A major injury (fracture, tear of ligament/muscle/cartilage, nerve injury),
- •Open skin lesion within the injured area,
- •History of three or more prior injuries (minor or major) to the actually injured region in the past,
- •Injury occurred more than 72 hours prior to study entry,
- •Injury is midline or involves the spine,
- •Haematoma is bigger than the size of one Tissugel plaster (10 x 14 cm),
- •Haematoma has a maximum diameter smaller than 4 cm,
- •Pain on movement <50 mm on a 100-mm Huskisson-type VAS,
- •Prior use of topical medication to involved area within 24 hours of study entry,
- •Prior use of OTC analgesic or NSAIDs (ibuprofen, ketoprofen) within 36 hours of study entry (acetaminophen permitted),
- •Prior use of narcotic analgesics within 7 days of study entry,
- •Prior use of systemic anti-inflammatory steroidal drugs, by any route of administration, within 60 days of study entry,
- •Prior use of long-acting NSAIDs such as piroxicam or naproxin since injury,
- •Concomitant use of drugs which may be susceptible to interactions with diclofenac or which may affect safety if used concomitantly (lithium, digoxin, anticoagulants, antidiabetic agents, cyclosporin, methotrexate, quinolone antimicrobials, other NSAIDs, steroids and diuretics),
- •Known hypersensitivity to diclofenac or other NSAID drugs (including aspirin),
- •Prior history of GI bleeds/ulcers, liver/kidney disease,
- •Patients with coagulation defects,
- •Patients with cardiac impairment,
- •Patients with allergic disorders, including asthma,
- •Pregnant women and women who are breast-feeding,
- •Patients participating or having been involved in other clinical investigations during the three months preceding the entry of this study,
- •Patients suffering from psychiatric diseases, not allowing the observance of the protocol, alcohol or drug abuse < 1 year,
- •Patients not able to understand the purposes of the study,
- •Patients refusing to give a written informed consent,
- •Patients not reliable, according to the investigator’s opinion.
研究者
相似试验
进行中（未招募）
不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Heparine in the treatment of ankle sprains. - NDankle sprainsMedDRA version: 9.1Level: LLTClassification code 10023229Term: Joint sprainEUCTR2006-003773-28-ITIBSA420
进行中（未招募）
1 期
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.Muscle contusion with hematoma and pain of upper or lower limbsEUCTR2005-003829-31-CZIBSA, Institut Biochimique S.A.330
进行中（未招募）
1 期
Multicentre, prospective, double-blind, in parallel groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of Betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis (tennis elbow)Chronic Lateral Elbow TendinopathyMedDRA version: 17.1Level: LLTClassification code 10043258Term: Tennis elbowSystem Organ Class: 100000004863MedDRA version: 17.1Level: LLTClassification code 10024032Term: Lateral epicondylitisSystem Organ Class: 100000004863EUCTR2014-004119-35-ITIBSA Institut Biochimique SA
已完成
不适用
A clinical study of the safety and effectiveness of ionized atelocollagen based adhesion barrier(Collabarrier®) for adhesion prevention in hysteroscopic surgeryKCT0002946Dalim Tissen188
进行中（未招募）
1 期
A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes.Type 2 DiabetesEUCTR2007-001049-16-GBovartis Pharmaceuticals UK Ltd